# Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018)

> **NCT01453634** · PHASE2 · WITHDRAWN · sponsor: **OPKO Health, Inc.**

## Conditions studied

- Stage 5 Chronic Kidney Disease (CKD)
- Secondary Hyperparathyroidism (SHPT)
- Hemodialysis (HD)

## Interventions

- **DRUG:** Lunacalcipol 180
- **DRUG:** Lunicalcipol 270

## Key facts

- **NCT ID:** NCT01453634
- **Lead sponsor:** OPKO Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-01
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The company is no longer pursuing this study.
- **Last updated:** 2014-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01453634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01453634, "Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01453634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*